Josh Seidenfeld

Josh is the global chair of Cooley’s digital health group and serves on Cooley’s Life Sciences Advisory Board. He represents life sciences, healthcare and technology clients through the full company life cycle, from seed stage through private financings, mergers & acquisitions and initial public offerings. He also regularly advises his clients on general corporate issues, securities matters and implications of proposed business transactions. 

Since 2018, Josh has handled 350+ venture capital financings with an aggregate deal value of more than $5 billion, including more than $2 billion in the past year. Josh counsels clients across industries – including companies operating in the biotechnology, therapeutics, pharma, climate tech and energy, digital health, medical technology and software sectors.

Josh previously worked in the healthcare industry at Practice Fusion, a web-based electronic health records company, where he was corporate counsel and director of business development. In this role, he was responsible for generating revenue, leading the company through complex regulations governing digital healthcare and records, negotiating contracts and more.

Josh is a contributing editor for Cooley GO, the firm’s online resource containing tools, documents, guidance and data for entrepreneurs and emerging companies. 

Josh’s select recent transactions include: 

• Zephyr AI’s $111 million Series A financing
• Cellares’ $255 million Series C financing
• Orca Bio’s $192 million Series B financing
• Helix’s $200 million Series B financing
• Rani Therapeutics’ $73 million IPO
• a16z’s investment in Carry1st’s $20 million Series A financing
• MycoWorks’ $125 million Series C financing
• MobileIron’s $100 million IPO
• Revance Therapeutics’ $110 million IPO
• Mindbody’s acquisition of Booker Software for $150 million
• Epinomics’ sale to 10x Genomics
• Jaspersoft’s acquisition by TIBCO for $185 million
• Apollo Endosurgery’s acquisition of the obesity intervention division of Allergan for $110 million
• Vaxart’s merger with Aviragen Therapeutics for $150 million
• Rovi’s acquisition of Veveo for an undisclosed amount
• Viki’s acquisition by Rakuten for an undisclosed amount
• 500friends’ acquisition by Merkle for an undisclosed amount 
• SoftBank Vision Fund’s lead $1.1 billion equity investment in Roivant Sciences
• Mist Systems’ $46 million Series C financing
• Cardiva Medical’s equity and debt financing
• Eero’s acquisition by Amazon for an undisclosed amount